Myeloproliferative Neoplasms | Specialty

Polycythemia Vera: Controlling HCT and WBC

July 10th 2018

Determining Inadequate Control or Intolerance in PV

July 10th 2018

Polycythemia Vera: Considerations for Frontline Therapy

July 10th 2018

Polycythemia Vera: Making a Diagnosis

July 10th 2018

Suspecting Polycythemia Vera: Challenges in Diagnosis

July 10th 2018

MPNs: Differentiating Between ET, PV, and MF

July 10th 2018

An Overview of Myeloproliferative Neoplasms

July 10th 2018

Expert Details Developments in MPN Paradigm

May 1st 2018

David S. Snyder, MD, details mutations and discusses investigational treatments within the field of myeloproliferative neoplasms.

Future Direction for Polycythemia Vera

April 26th 2018

PV: Treatment With Ruxolitinib

April 26th 2018

Rationale for JAK Inhibition in PV

April 26th 2018

PV: Clinical Use of Hydroxyurea

April 26th 2018

Clinical Control of Polycythemia Vera

April 26th 2018

Initial Approach to PV Treatment

April 26th 2018

Dr. Snyder on Ruxolitinib in Patients With Myelofibrosis

April 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.

PV Treatment Landscape Balancing Effective Regimens With QOL Challenges

April 18th 2018

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

JAK Signaling Remains a Promising Target in Myeloproliferative Neoplasms

April 10th 2018

Srdan Verstovsek, MD, PhD, discusses the rationale for targeting JAK signaling, new drugs under study for this pathway, and clinical challenges associated with these therapies.

Novel Approaches Show Promise in Targeting JAK Pathway

February 12th 2018

Dysregulation of the JAK pathway plays a role in the development of numerous tumor types; it is particularly central to the pathophysiology of myelofibrosis and has long been recognized as a potentially valuable therapeutic target in that malignancy.

Ropeginterferon Alfa-2b Demonstrates Durable Activity in Polycythemia Vera

December 21st 2017

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.

Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up

December 20th 2017

Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.